The Science of Mold Biotoxins & HLA Genetics

Within the CIRS model, roughly a quarter of people are estimated to carry HLA-DR gene variants that proponents say prevent the immune system from recognizing mold biotoxins — so the body never tags them for removal and they recirculate.

The account that follows describes how CIRS researchers propose this works; it is a hypothesis from that literature, not settled mainstream immunology.

This is the central question that connects CIRS, TILT, and MCS. The answer lies in the Human Leukocyte Antigen (HLA) system — specifically the HLA-DR genes on Chromosome 6.

In a normal immune response, HLA-DR proteins on the surface of immune cells act as presentation platforms. They grab fragments of foreign substances (antigens) and display them to T-cells, which then signal B-cells to produce antibodies. Those antibodies mark the foreign substance for clearance — enabling immune cells in the liver and spleen to recognize, capture, and eliminate it through normal detoxification and excretion pathways.

In people with certain HLA-DR gene variants, the shape of the HLA-DR protein does not effectively grip biotoxin fragments. The immune system literally cannot “see” the toxin. No presentation occurs, no antibodies are produced, and no tag is created. The toxin passes through the liver unrecognized.

This is not a liver problem or a detoxification enzyme deficiency (though those can coexist). It is an immune identification problem. The liver works fine — it is waiting for a tag that never arrives.

HLA-DR genotyping is a one-time blood test available through LabCorp and Quest. The results do not change over time — your HLA genes are fixed for life. A single test provides a permanent answer about your genetic susceptibility to biotoxin illness. See the MCS testing page for how to get it ordered.

Untagged biotoxins enter a continuous recycling loop called enterohepatic recirculation. They pass through the liver into bile, are reabsorbed in the small intestine, and return to the bloodstream — indefinitely.

When the immune system fails to tag a biotoxin, the liver still processes it through bile — because that is what the liver does with fat-soluble compounds. The toxin enters the small intestine via bile. In a healthy clearance scenario, tagged toxins would be excreted. But untagged toxins are reabsorbed through the intestinal wall and sent right back into the bloodstream.

This creates a self-perpetuating loop. The person can leave the moldy building, move to a clean environment, and still carry a circulating biotoxin load for months or years. A 2024 peer-reviewed case series documented this directly: in individuals with HLA-DR variants, ochratoxin A clearance was approximately 10 times slower than normal, and mycophenolic acid clearance was approximately 213 times slower. Full clearance was projected to take 2 to 4 years after exposure ended.

While the toxins circulate, they continuously stimulate the innate immune system — the body’s first responders. The innate system recognizes that something is wrong but cannot fix the problem (that requires the adaptive system, which is blind to these specific toxins). Instead, it releases inflammatory chemicals called cytokines in an unregulated cascade. This chronic inflammation is CIRS.

HLA-DR haplotypes are grouped by susceptibility type: multi-susceptible, mold-susceptible, post-Lyme susceptible, and low-MSH variants. A simple blood test identifies your specific pattern.

The Shoemaker research categorizes HLA-DR/DQ haplotypes using a three-number notation (e.g., 4-3-53) derived from the DRB1, DQB1, and DRB3/4/5 gene results. Each combination maps to a susceptibility profile:

An online calculator at myhousemakesmesick.com accepts the two-digit values from your LabCorp or Quest HLA-DR/DQ report and converts them into the haplotype categories shown above. This is a free tool — you enter your allele numbers and it identifies your susceptibility profile.

Within the CIRS framework, roughly 24–25% of the general population is estimated to carry at least one HLA variant associated with biotoxin susceptibility. Not all variants are treated as equal risk — the multi-susceptible haplotypes (particularly 4-3-53) are, in this model, associated with the most severe and prolonged illness when biotoxin exposure occurs. (These percentages and haplotype categories originate in the Shoemaker research and are not independently confirmed in mainstream genetics.)

Chronic biotoxin recirculation depletes melanocyte-stimulating hormone (MSH), a master regulatory peptide. Low MSH causes cascading failures in sleep, pain regulation, gut integrity, hormone production, and antimicrobial defense.

MSH (melanocyte-stimulating hormone) is produced in the hypothalamus and has far more functions than its name suggests. It regulates inflammation, modulates pain perception, controls sleep cycles via melatonin production, maintains intestinal barrier integrity, and supports antimicrobial peptide production.

When the innate immune system stays activated — as it does during chronic biotoxin recirculation — cytokine overproduction suppresses MSH production. The downstream effects explain many symptoms that CIRS and MCS patients experience but struggle to connect to a single cause:

MARCoNS are antibiotic-resistant staph bacteria that colonize deep nasal passages when MSH is low. They produce biofilm that further suppresses MSH, creating a self-reinforcing cycle that blocks recovery.

Multiple Antibiotic Resistant Coagulase Negative Staphylococci (MARCoNS) are a specific type of staph bacteria found in the deep nasal passages of many CIRS patients. They are not the same as a sinus infection — standard nasal cultures often miss them because they live deeper than typical swabs reach.

MARCoNS thrive in the low-MSH environment created by chronic inflammation. Once established, they produce biofilm — a protective coating that makes them resistant to antibiotics and further suppresses MSH production. This creates a self-reinforcing cycle: low MSH allows MARCoNS to colonize, and MARCoNS further reduce MSH.

Testing for MARCoNS requires a deep nasal swab (API-Staph test through Microbiology Dx or similar lab). Standard ENT evaluations typically will not detect them. Eradication usually involves BEG spray (Bactroban, EDTA, and Gentamicin) compounded by a specialty pharmacy, though this treatment must be coordinated with the broader CIRS protocol — clearing MARCoNS without first reducing the biotoxin load can cause recolonization.

The treatment path that puts all of this to work — binders, MARCoNS eradication, and sequential biomarker correction — is the Shoemaker Protocol, on the Mold & MCS page.